Trial Suggests Optimal Approach to Unresectable CRC Liver Mets FOLFOXIRI plus bevacizumab "preferred" for certain tumors Jun 20, 2023
Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivors A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
Daily Low-Dose Aspirin Upped Incidence of Anemia in Older Adults An analysis of the ASPREE trial showed 100-mg aspirin led to more anemia events vs placebo Jun 19, 2023
Breast Cancer Drugs May Weaken Effects of Weight-Loss Drugs Survivors on aromatase inhibitors lost significantly less weight Jun 18, 2023
New Bispecific Antibody Approved for Tough-to-Treat Lymphoma Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate Jun 16, 2023
Cystic Renal Masses Often Harbor High-Grade Disease No link between grade and cancer-specific survival, active surveillance still an option for many Jun 16, 2023
Early Invasive Breast Cancer Now Leaves Mostly Long-Term Survivors Mortality risk has decreased substantially since the 1990s Jun 15, 2023
Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis Patients with depression alone had the worst overall survival Jun 13, 2023
CRISPR Therapy Exceeds Targets in Thalassemia, Sickle Cell Disease Results "indicate that exa-cel can provide a one-time functional cure," says researcher Jun 13, 2023
Parents' Goals for Pediatric Palliative Care Change Over Time Quality of life ranked as most important overall Jun 12, 2023
Breast Ultrasound Recs May Not Be Targeting the Right Women It's not just dense breasts that matter, researchers say Jun 12, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Healthcare Violence Breaks Record; U.K. Limits Puberty Blockers; HPV Discoverer Dies Health news and commentary from around the Web gathered by MedPage Today staff Jun 12, 2023
Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
Acute GvHD Risk After Allo-HCT Higher With Some Antibiotics vs Others Findings could pave the way for considering common complication in stewardship programs Jun 08, 2023
TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
Drug Shortage Worsens; AI, 3D Printing Potential Grows; Cancer's Effect on Function News, features, and commentary about cancer-related issues Jun 08, 2023
How Vax Skeptics Sow Doubt; Gun Death Every 11 Minutes; 90210 Star's Cancer Spreads Health news and commentary from around the Web gathered by MedPage Today staff Jun 08, 2023
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says Jun 07, 2023
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC The strategy also led to increased toxicity Jun 06, 2023
New Data in NSCLC Bolster Support for Perioperative Immunotherapy EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma The CAR T-cell therapy led to significantly longer overall survival Jun 05, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
Sickle Cell Disease Poses Major Risk for Pregnant Black Patients Condition may exacerbate racial disparities in severe maternal morbidity Jun 05, 2023
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
Omitting RT Safe in Many Locally Advanced Rectal Cancers Most intermediate-risk cases can be cured without pelvic radiation, says investigator Jun 05, 2023
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert Jun 04, 2023
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease Jun 04, 2023
New Standard in Operable EGFR-Positive Lung Cancer "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
How a Medical Recoding May Limit Cancer Patients’ Options for Breast Reconstruction Many believe this would restrict women's options for surgery Jun 04, 2023
New Ovarian Cancer Drug Extends Survival in Resistant Disease "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer Survival 13 months better with surgery, but "curiosities" in neoadjuvant arm muddy the results Jun 04, 2023
Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer Response rates reached 41-47% with different approaches in rare disease Jun 03, 2023
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET Jun 03, 2023